Ganaxolone
| Clinical data | |
|---|---|
| Trade names | Ztalmy |
| Other names | GNX; CCD-1042; 3β-Methyl-5α-pregnan-3α-ol-20-one; 3α-Hydroxy-3β-methyl-5α-pregnan-20-one |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Neurosteroid |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.210.937 |
| Chemical and physical data | |
| Formula | C22H36O2 |
| Molar mass | 332.528 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures in people with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder.[1][3] Ganaxolone is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator.[1]
The most common side effects of treatment with ganaxolone include somnolence (sleepiness), fever, excessive saliva or drooling, and seasonal allergy.[4]
Ganaxolone was approved for medical use in the United States in March 2022,[1][4][5] and in the European Union in July 2023.[2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[6][7]
Medical uses
[edit]Ganaxolone is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder.[1][2][8][9]
Pharmacology
[edit]Mechanism of action
[edit]Ganaxolone is a synthetic analog of the endogenous neurosteroid allopregnanolone and acts as a positive allosteric modulator of GABAA receptors.[13] Like other neurosteroids, it binds to specific allosteric sites on the receptor and enhances chloride ion flux, producing neuronal hyperpolarization and increased inhibitory signaling.[3][10][11] Electrophysiological and animal studies show that ganaxolone potentiates both synaptic (phasic) and extrasynaptic (tonic) GABAA receptors, including δ subunit–containing receptors, thereby raising seizure threshold and limiting seizure propagation.[3] This mechanism is consistent with the established actions of allopregnanolone and other pregnane neurosteroids.
The neurosteroid modulation of GABAA receptors by progesterone-derived metabolites such as allopregnanolone was first characterized in the mid-1980s by Majewska and colleagues, who demonstrated potent enhancement of GABAergic inhibition by these endogenous steroids (1986–1987). Subsequent review articles in the late 1980s and early 1990s further established this mechanism, providing the conceptual basis for later synthetic analogs such as ganaxolone.[10][11][12]
Ganaxolone is thought to modulate both synaptic and extrasynaptic GABAA receptors to normalize over-excited neurons.[3] Ganaxolone's activation of the extrasynaptic receptor is an additional mechanism that provides stabilizing effects that potentially differentiates it from other drugs that increase GABA signaling.[3]
Ganaxolone binds to allosteric sites of the GABAA receptor to modulate and open the chloride ion channel, resulting in a hyperpolarization of the neuron.[3] This causes an inhibitory effect on neurotransmission, reducing the chance of a successful action potential (depolarization) from occurring.[3][13][14]
It is unknown whether ganaxolone possesses significant hormonal activity in vivo, with a 2020 study finding evidence of in vitro binding to the membrane progesterone receptor.[15]
Chemistry
[edit]Other pregnane neurosteroids include endogenous metabolites such as allopregnanolone and pregnanolone (eltanolone), as well as synthetic analogs including alfaxolone, alfadolone, hydroxydione, minaxolone and renanolone. These compounds share the characteristic 5α‑reduced pregnane backbone and act as positive allosteric modulators of GABAA receptors, although they differ in potency, pharmacokinetics and clinical applications[16]
History
[edit]The FDA approved ganaxolone based on evidence from a single, double-blind, randomized, placebo-controlled study (Study 1, NCT03572933) of 101 participants with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder who were two years of age and older.[4] The trial was conducted at 36 sites in 8 countries including Australia, France, Israel, Italy, Poland, Russian Federation, the United Kingdom, and the United States.[4] Forty-four (40.7%) of the participants were from US sites.[4] Safety was assessed from a pool of two clinical studies.[4] These include the study of participants with cyclin-dependent kinase-like 5 deficiency disorder and a clinical study that included seven additional participants from a trial of ganaxolone in children and young adults.[4][17][18][19]
References
[edit]- 1 2 3 4 5 "Ztalmy- ganaxolone suspension". DailyMed. 15 November 2022. Archived from the original on 21 January 2023. Retrieved 21 January 2023.
- 1 2 3 "Ztalmy EPAR". European Medicines Agency. 31 July 2023. Archived from the original on 25 August 2023. Retrieved 25 August 2023.
- 1 2 3 4 5 Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, et al. (March 1997). "Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor". The Journal of Pharmacology and Experimental Therapeutics. 280 (3): 1284–1295. doi:10.1016/S0022-3565(24)36511-5. PMID 9067315.
- 1 2 3 4 5 6 7 Center for Drug Evaluation and Research (18 March 2022). "Drug Trials Snapshots: Ztalmy". U.S. Food and Drug Administration. FDA. Retrieved 9 October 2023.
This article incorporates text from this source, which is in the public domain. - ↑ Lamb YN (June 2022). "Ganaxolone: First Approval". Drugs. 82 (8): 933–940. doi:10.1007/s40265-022-01724-0. PMID 35596878.
- ↑ Center for Drug Evaluation and Research (10 January 2023). "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). FDA. Archived from the original on 21 January 2023. Retrieved 22 January 2023.
This article incorporates text from this source, which is in the public domain. - ↑ New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024.
This article incorporates text from this source, which is in the public domain. - ↑ Gould A, Amin S (July 2024). "An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder". Expert Review of Neurotherapeutics. 24 (10): 945–951. doi:10.1080/14737175.2024.2385937. PMID 39082513.
- ↑ Khan P, Saini S, Hussain S, Majid H, Gupta S, Agarwal N (April 2024). "A systematic review and meta-analysis on efficacy and safety of Ganaxolone in epilepsy". Expert Opinion on Pharmacotherapy. 25 (5): 621–632. doi:10.1080/14656566.2024.2342413. PMID 38606458.
- ↑ Majewska MD, Harrison NL, Schwartz RD, Barker JL, Paul SM (May 1986). "Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor". Science. 232 (4753). New York, N.Y.: 1004–1007. doi:10.1126/science.2422758. PMID 2422758.
- ↑ Majewska MD (November 1987). "Steroids and brain activity. Essential dialogue between body and mind". Biochemical Pharmacology. 36 (22): 3781–3788. doi:10.1016/0006-2952(87)90437-0. PMID 2825703.
- ↑ Majewska MD (1992). "Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance". Progress in Neurobiology. 38 (4): 379–395. doi:10.1016/0301-0082(92)90025-a. PMID 1349441.
- ↑ Kaminski RM, Livingood MR, Rogawski MA (July 2004). "Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice". Epilepsia. 45 (7): 864–867. doi:10.1111/j.0013-9580.2004.04504.x. PMID 15230714. S2CID 21974013.
- ↑ Reddy DS, Rogawski MA (May 2010). "Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model". Epilepsy Research. 89 (2–3): 254–260. doi:10.1016/j.eplepsyres.2010.01.009. PMC 2854307. PMID 20172694.
- ↑ Thomas P, Pang Y (24 June 2020). "Anti-apoptotic Actions of Allopregnanolone and Ganaxolone Mediated Through Membrane Progesterone Receptors (PAQRs) in Neuronal Cells". Frontiers in Endocrinology. 11 (417) 417. Lausanne. doi:10.3389/fendo.2020.00417. PMC 7331777. PMID 32670200.
- ↑ US 20190160078A1, Masuoka LK, Lappalainen J, "Ganaxolone for use in treating genetic epileptic disorders", published 30 May 2019, issued 30 May 2019, assigned to Marinus Pharmaceuticals Inc and Immedica Pharma US Inc
- ↑ Dell'Isola GB, Siciliano M, D'Onofrio G, Ferrara P, Striano P, Carotenuto M, et al. (December 2025). "Ganaxolone in Epilepsy: Insights into a Neurosteroid-Based Therapy". Epilepsy Research. 218 107669. doi:10.1016/j.eplepsyres.2025.107669. PMID 41033234.
- ↑ Al-Qahtani Z, Al-Kuraishy HM, Hussain NR, Waheed HJ, Al-Gareeb AI, Albuhadily AK, et al. (November 2025). "Molecular mechanisms of neurosteroids in temporal lobe epilepsy: current insights and therapeutic perspectives". Molecular Biology Reports. 53 (1) 124. doi:10.1007/s11033-025-11238-z. PMID 41296082.
- ↑ Chang W, Kwak AS, Han SH, Song DY, Yoo HI, Lee JH (August 2026). "Epilepsy as a Multiscale Network Disorder: Integrating Precision Therapeutics and Emerging Experimental Platforms". Pharmaceutics. 18 (8): 969. doi:10.3390/pharmaceutics18080969. PMC 13516588. PMID 42654085.
External links
[edit]- Clinical trial number NCT03572933 for "Study of Adjunctive Ganaxolone Treatment in Children and Young Adults With CDKL5 Deficiency Disorder (Marigold)" at ClinicalTrials.gov